We are part of
ABAXYS aims to reduce significantly the time-to-clinics of preclinical programs and contribute to develop efficacious disease modifying therapies for brain neurodegenerative diseases
Our neuroscience discovery efforts identified new therapeutic strategies aiming disease-modifying interventions by small chemical molecules and gene therapies
Own technological platforms on Big-data mining, high-resolution bio-imaging and disease-modeling strengthen the pre-clinical pipeline
Abaxys Therapeutics is advancing new medicinal drugs for the treatment of human neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease
The company is at the center of a strong strategic partnership network with a constellation of top academic institutions and small biotechs in the area of neurosciences
With our Data Mining approach, we are able to efficiently identify new Hits.
With our Big Data and Simulation approach, we are able to accelerate the Preclinical process (from 3-5 years in only 6 months) by replacing lab, in-vitro, in-vivo experience with in-sillico validation.
With our Bio-imaging approach, we do not have to kill the Animal Model to see the impact of a drug. Thus we are able to follow the evolution of the disease, see the impact of a molecule and better predict the efficacy in human.